Skip to main content
Back
Watch Compare

Bolt Biotherapeutics, Inc.

Data quality: 100%
BOLT
Nasdaq Manufacturing Chemicals
$4.51
▼ $0.09 (-1.96%)
Mkt Cap: 8.67 M
Price
$4.51
Mkt Cap
8.67 M
Day Range
$4.50 — $4.70
52-Week Range
$3.91 — $9.24
Volume
6,440
Open $4.68
50D / 200D Avg
$4.92
8.38% below
50D / 200D Avg
$5.38
16.09% below

Quick Summary

Key Takeaways

Revenue grew 57.20% annually over 5 years — strong growth
Negative free cash flow of -39.92 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 57.13%
Capital efficient — spends only 0.94% of revenue on capex

Growth

Revenue Growth (5Y)
57.20%
Above sector avg (1.82%)
Revenue (1Y)0.07%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-94.09%
Below sector avg (-53.41%)
ROIC-48.24%
Net Margin-433.74%
Op. Margin-469.30%

Safety

Debt / Equity
N/A
Current Ratio3.57
Interest CoverageN/A

Valuation

PE (TTM)
-0.26
Above sector avg (-1.48)
P/B Ratio0.27
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.3 -1.5
P/B 0.3 1.6
ROE % -94.1 -53.4
Net Margin % -433.7 -41.5
Rev Growth 5Y % 57.2 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0.07% Revenue Growth (3Y) -1.16%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 57.20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7.70 M Net Income (TTM) -33.38 M
ROE -94.09% ROA -47.49%
Gross Margin N/A Operating Margin -469.30%
Net Margin -433.74% Free Cash Flow (TTM) -39.92 M
ROIC -48.24% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.57
Interest Coverage N/A Asset Turnover 0.11
Working Capital 25.64 M Tangible Book Value 32.10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.26 Forward P/E N/A
P/B Ratio 0.27 P/S Ratio 1.13
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -460.66%
Market Cap 8.67 M Enterprise Value -9.09 M
Per Share
EPS (Diluted TTM) -17.85 Revenue / Share 4.00
FCF / Share -20.78 OCF / Share -20.74
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.94% FCF Conversion 119.61%
SBC-Adj. FCF -42.76 M Growth Momentum -57.13

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.70 M 7.69 M 7.88 M 5.73 M 1.26 M
Net Income -33.38 M -63.12 M -69.20 M -88.10 M -98.59 M
EPS (Diluted) -17.85 -1.65 -1.83 -2.36 —
Gross Profit — — — — —
Operating Income -36.11 M -73.05 M -76.20 M -90.32 M -92.79 M
EBITDA — — — — —
R&D Expenses 28.53 M 57.47 M 61.54 M 73.12 M 75.66 M
SG&A Expenses — — — — —
D&A 1.29 M 1.78 M 1.85 M 1.67 M 1.19 M
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 56.75 M 99.63 M 159.78 M 227.81 M 307.72 M
Total Liabilities 30.24 M 42.43 M 47.04 M 56.30 M 57.60 M
Shareholders' Equity 26.51 M 57.20 M 112.74 M 171.51 M 250.12 M
Total Debt — — — — —
Cash & Equivalents 11.70 M 7.21 M 10.81 M 9.24 M 27.38 M
Current Assets 30.26 M 50.81 M 105.71 M 172.75 M 189.16 M
Current Liabilities 8.44 M 15.86 M 20.46 M 23.12 M 21.33 M